MedTrace Logo

Interest of Biofer ® Compound Used in Blédilait Follow on Milk in Infant With Latent Iron Deficiency

NCT00554814 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2008-11-17

No results posted yet for this study

Summary

The primary purpose of the study is to demonstrate the superiority of Bledilait milk (Biofer® 2mg/100kcal) in comparison with ferrous sulphate supplemented milk (2 mg/100 kcal) in infants (6 to 12 months) with latent iron deficiency by measuring serum ferritin value after 2 months of consumption of studied milks.

Conditions

  • Latent Iron Deficiency

Interventions

DRUG

Bledilait Biofer®

Bledilait Biofer® 2 mg/100 kcal

DRUG

Milk supplemented with ferrous sulphate

Milk supplemented with ferrous sulphate (2mg/100kcal)

DRUG

Blédilait Biofer®

Blédilait Biofer® milk (1,1mg/100kcal)

Sponsors & Collaborators

  • Bledina

    lead INDUSTRY

Principal Investigators

  • Jacques LANGUE

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00554814 on ClinicalTrials.gov